Incidence, risk factors, and pathogenesis of second malignancies in patients with non-Hodgkin lymphoma

References

• National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 13 Regs Public-Use, Nov 2004 Sub (1973 – 2002 varying), released April 2005, based on the November 2004 submission
   Google Scholar
• Cancer Facts and Figures 2005. American Cancer Society, Atlanta, Ga 2005
   Google Scholar
• Tward J D, Wendland M M, Shrieve D C, Szabo A, Gaffney D K. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 2006; 107: 108–115
   PubMed Web of Science ®Google Scholar
• Travis L B, Curtis R E, Boice J D, Jr, Fraumeni J F, Jr. Bladder cancer after chemotherapy for non-Hodgkin's lymphoma. N Engl J Med 1989; 321: 544–545
   PubMed Web of Science ®Google Scholar
• Travis L B, Curtis R E, Boice J D, Jr, Hankey B F, Fraumeni J F, Jr. Second cancers following non-Hodgkin's lymphoma. Cancer 1991; 67: 2002–2009
   PubMed Web of Science ®Google Scholar
• Travis L B, Curtis R E, Glimelius B, Holowaty E, Van Leeuwen F E, Lynch C F, et al. Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst 1993; 85: 1932–1937
   PubMed Web of Science ®Google Scholar
• Travis L B, Curtis R E, Glimelius B, Holowaty E J, Van Leeuwen F E, Lynch C F, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995; 87: 524–530
   PubMed Web of Science ®Google Scholar
• Brennan P, Coates M, Armstrong B, Colin D, Boffetta P. Second primary neoplasms following non-Hodgkin's lymphoma in New South Wales, Australia. Br J Cancer 2000; 82: 1344–1347
   PubMed Web of Science ®Google Scholar
• Brennan P, Scelo G, Hemminki K, Mellemkjaer L, Tracey E, Andersen A, et al. Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma. Br J Cancer 2005; 93: 159–166
   PubMed Web of Science ®Google Scholar
• Okines A, Thomson C S, Radstone C R, Horsman J M, Hancock B W. Second primary malignancies after treatment for malignant lymphoma. Br J Cancer 2005; 93: 418–424
   PubMed Web of Science ®Google Scholar
• Mudie N Y, Swerdlow A J, Higgins C D, Smith P, Qiao Z, Hancock B W, et al. Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study. J Clin Oncol 2006; 24: 1568–1574
   PubMed Web of Science ®Google Scholar
• Greene M H, Young R C, Merrill J M, DeVita V T. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma. Cancer Res 1983; 43: 1891–1898
   PubMed Web of Science ®Google Scholar
• Andre M, Mounier N, Leleu X, Sonet A, Brice P, Henry-Amar M, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood 2004; 103: 1222–1228
   PubMed Web of Science ®Google Scholar
• Armitage J O, Carbone P P, Connors J M, Levine A, Bennett J M, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003; 21: 897–906
   PubMed Web of Science ®Google Scholar
• Darrington D L, Vose J M, Anderson J R, Bierman P J, Bishop M R, Chan W C, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994; 12: 2527–2534
   PubMed Web of Science ®Google Scholar
• Lavey R S, Eby N L, Prosnitz L R. Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas. Cancer 1990; 66: 80–88
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Schiegnitz E, Haferlach T, Hasford J, Unterhalt M, et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004; 22: 4926–4933
   PubMed Web of Science ®Google Scholar
• Oddou S, Vey N, Viens P, Bardou V J, Faucher C, Stoppa A M, et al. Second neoplasms following high-dose chemotherapy and autologous stem cell transplantation for malignant lymphomas: a report of six cases in a cohort of 171 patients from a single institution. Leuk Lymphoma 1998; 31: 187–194
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Jonsson V, Pedersen M, Hou-Jensen K. Leiomyosarcoma of the urinary bladder after cyclophosphamide. J Clin Oncol 1995; 13: 532–533
   PubMed Web of Science ®Google Scholar
• Stone R M, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe S N, et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 2535–2542
   PubMed Web of Science ®Google Scholar
• Moertel C G, Hagedorn A B. Leukemia or lymphoma and coexistent primary malignant lesions: a review of the literature and a study of 120 cases. Blood 1957; 12: 788–803
   PubMed Web of Science ®Google Scholar
• Berg J W. The incidence of multiple primary cancers. I. Development of further cancers in patients with lymphomas, leukemias, and myeloma. J Natl Cancer Inst 1967; 38: 741–752
   PubMed Web of Science ®Google Scholar
• Zarrabi M H. Association of non-Hodgkin's lymphoma (NHL) and second neoplasms. Semin Oncol 1980; 7: 340–351
   PubMed Web of Science ®Google Scholar
• MacDougall B K, Weinerman B H, Kemel S. Second malignancies in non-Hodgkin's lymphoma. Cancer 1981; 48: 1299–1301
   PubMed Web of Science ®Google Scholar
• Storm H H, Prener A. Second cancer following lymphatic and hematopoietic cancers in Denmark, 1943 – 80. Natl Cancer Inst Monogr 1985; 68: 389–409
   PubMedGoogle Scholar
• Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller-Hermelink H K, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849
   PubMed Web of Science ®Google Scholar
• National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909–3918
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Ersboll J, Hansen V L, Sorensen B L, Christoffersen K, Hou-Jensen K, et al. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med 1988; 318: 1028–1032
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Ersboll J, Sorensen H M, Keiding N, Larsen S O, Philip P, et al. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann Intern Med 1985; 103: 195–200
   PubMed Web of Science ®Google Scholar
• Boice J D. Cancer following medical irradiation. Cancer 1981; 47(5 Suppl)1081–1090
   PubMed Web of Science ®Google Scholar
• Boice J D, Jr. Radiation and breast carcinogenesis. Med Pediatr Oncol 2001; 36: 508–513
   PubMedGoogle Scholar
• Travis L B, Weeks J, Curtis R E, Chaffey J T, Stovall M, Banks P M, et al. Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma. J Clin Oncol 1996; 14: 565–571
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Daugaard G, Hansen S W, Philip P, Larsen S O, Rorth M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 1991; 338: 359–363
   PubMed Web of Science ®Google Scholar
• Travis L B. The epidemiology of second primary cancers. Cancer Epidemiol Biomarkers Prev 2006; 15: 2020–2026
   PubMed Web of Science ®Google Scholar
• Behrens C, Travis L B, Wistuba, II, Davis S, Maitra A, Clarke E A, et al. Molecular changes in second primary lung and breast cancers after therapy for Hodgkin's disease. Cancer Epidemiol Biomarkers Prev 2000; 9: 1027–1035
   PubMed Web of Science ®Google Scholar
• De Benedetti V M, Travis L B, Welsh J A, van Leeuwen F E, Stovall M, Clarke E A, et al. p53 mutations in lung cancer following radiation therapy for Hodgkin's disease. Cancer Epidemiol Biomarkers Prev 1996; 5: 93–98
   PubMed Web of Science ®Google Scholar
• Khan M A, Travis L B, Lynch C F, Soini Y, Hruszkewycz A M, Delgado R M, et al. p53 mutations in cyclophosphamide-associated bladder cancer. Cancer Epidemiol Biomarkers Prev 1998; 7: 397–403
   PubMed Web of Science ®Google Scholar
• Leonard D G, Travis L B, Addya K, Dores G M, Holowaty E J, Bergfeldt K, et al. p53 mutations in leukemia and myelodysplastic syndrome after ovarian cancer. Clin Cancer Res 2002; 8: 973–985
   PubMed Web of Science ®Google Scholar
• Allan J M, Travis L B. Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer 2005; 5: 943–955
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Philip P, Larsen S O, Andersson M, Daugaard G, Ersboll J, et al. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 1993; 7: 1975–1986
   PubMed Web of Science ®Google Scholar
• Baldwin E L, Osheroff N. Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents 2005; 5: 363–372
   PubMedGoogle Scholar
• Kelly L M, Gilliland D G. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 2002; 3: 179–198
   PubMed Web of Science ®Google Scholar
• Orlandi E, Lazzarino M, Bernasconi P, Astori C, Bernasconi C. Secondary acute myeloid leukemia following treatment with VP16-containing regimens for non-Hodgkin's lymphoma. Haematologica 1998; 83: 758–759
   PubMed Web of Science ®Google Scholar
• Larson R A, Wang Y, Banerjee M, Wiemels J, Hartford C, Le Beau M M, et al. Prevalence of the inactivating 609C–>T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 1999; 94: 803–807
   PubMed Web of Science ®Google Scholar
• Naoe T, Takeyama K, Yokozawa T, Kiyoi H, Seto M, Uike N, et al. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res 2000; 6: 4091–4095
   PubMed Web of Science ®Google Scholar
• Allan J M, Wild C P, Rollinson S, Willett E V, Moorman A V, Dovey G J, et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci USA 2001; 98: 11592–11597
   PubMed Web of Science ®Google Scholar
• Roboz G J, Bennett J M, Coleman M, Ritchie E K, Furman R R, Rossi A, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma. Leuk Res 2007
   Web of Science ®Google Scholar
• Halperin E C. Particle therapy and treatment of cancer. Lancet Oncol 2006; 7: 676–685
   PubMed Web of Science ®Google Scholar
• Hall E. Radiobiology for the Radiobiologist. JB Lippincott Co., Philadelphia 1988
   Google Scholar
• Aust A E, Eveleigh J F. Mechanisms of DNA oxidation. Proc Soc Exp Biol Med 1999; 222: 246–252
   PubMed Web of Science ®Google Scholar
• Hall E. Radiobiology for the Radiobiologist5th ed. JB Lippincott Co., Philadelphia 2000
   Google Scholar
• Dong C, Hemminki K. Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958 – 1996: a search for common mechanisms. Br J Cancer 2001; 85: 997–1005
   PubMed Web of Science ®Google Scholar
• van Leeuwen F E, Klokman W J, Stovall M, Dahler E C, van't Veer M B, Noordijk E M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003; 95: 971–980
   PubMed Web of Science ®Google Scholar
• Travis L B, Hill D A, Dores G M, Gospodarowicz M, van Leeuwen F E, Holowaty E, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. Jama 2003; 290: 465–475
   PubMed Web of Science ®Google Scholar
• Latz D, Nassar N, Frank R. Trofosfamide in the palliative treatment of cancer: a review of the literature. Onkologie 2004; 27: 572–576
   PubMed Web of Science ®Google Scholar
• Gandhok N, Sartor O. Unexpected response of hormone-refractory prostate cancer to treatment with an antileukemic chemotherapy regimen. Urology 2004; 64: 807–809
   PubMed Web of Science ®Google Scholar
• Patel A V, Rodriguez C, Jacobs E J, Solomon L, Thun M J, Calle E E. Recreational physical activity and risk of prostate cancer in a large cohort of U.S. men. Cancer Epidemiol Biomarkers Prev 2005; 14: 275–279
   PubMed Web of Science ®Google Scholar
• Greenwald P. Lifestyle and medical approaches to cancer prevention. Recent Results Cancer Res 2005; 166: 1–15
   PubMedGoogle Scholar
• Amling C L. The association between obesity and the progression of prostate and renal cell carcinoma. Urol Oncol 2004; 22: 478–484
   PubMed Web of Science ®Google Scholar
• West J G, Qureshi A, West J E, Chacon M, Sutherland M L, Haghighi B, et al. Risk of angiosarcoma following breast conservation: a clinical alert. Breast J 2005; 11: 115–123
   PubMed Web of Science ®Google Scholar
• Rubino C, Shamsaldin A, Le M G, Labbe M, Guinebretiere J M, Chavaudra J, et al. Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment. Breast Cancer Res Treat 2005; 89: 277–288
   PubMed Web of Science ®Google Scholar
• Pothuri B, Ramondetta L, Martino M, Alektiar K, Eifel P J, Deavers M T, et al. Development of endometrial cancer after radiation treatment for cervical carcinoma. Obstet Gynecol 2003; 101(5 Pt 1)941–945
   PubMed Web of Science ®Google Scholar
• Moser E C, Noordijk E M, van Leeuwen F E, Baars J W, Thomas J, Carde P, et al. Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study. Haematologica 2006; 91: 1481–1488
   PubMed Web of Science ®Google Scholar
• Travis L B, Curtis R E, Stovall M, Holowaty E J, van Leeuwen FE, Glimelius B, et al. Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst 1994; 86: 1450–1457
   PubMed Web of Science ®Google Scholar
• Travis L B, Rabkin C S, Brown L M, Allan J M, Alter B P, Ambrosone C B, et al. Cancer survivorship – genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 2006; 98: 15–25
   PubMed Web of Science ®Google Scholar
• Blume K G. Autologous or allogeneic hematopoietic cell transplantation for non-Hodgkin's lymphoma?. Ann Hematol 2002; 81(Suppl 2)S9–S11
   Google Scholar
• Horwitz S M, Negrin R S, Blume K G, Breslin S, Stuart M J, Stockerl-Goldstein K E, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004; 103: 777–783
   PubMed Web of Science ®Google Scholar
• Nademanee A, Forman S, Molina A, Fung H, Smith D, Dagis A, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005; 106: 2896–2902
   PubMed Web of Science ®Google Scholar
• Vose J M, Bierman P J, Enke C, Hankins J, Bociek G, Lynch J C, et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 461–467
   PubMed Web of Science ®Google Scholar
• Khouri I F. Reduced-intensity regimens in allogeneic stem-cell transplantation for non-hodgkin lymphoma and chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2006; 390–397
   PubMedGoogle Scholar
• Law L Y, Horning S J, Wong R M, Johnston L J, Laport G G, Lowsky R, et al. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2006; 12: 703–711
   PubMed Web of Science ®Google Scholar
• Maloney D G. Graft-vs.-lymphoma effect in various histologies of non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44(Suppl 3)S99–S105
   PubMed Web of Science ®Google Scholar
• Bhatia S, Ramsay N K, Steinbuch M, Dusenbery K E, Shapiro R S, Weisdorf D J, et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633–3639
   PubMed Web of Science ®Google Scholar
• Deeg H J, Socie G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood 1998; 91: 1833–1844
   PubMed Web of Science ®Google Scholar
• Kolb H J, Socie G, Duell T, Van Lint M T, Tichelli A, Apperley J F, et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med 1999; 131: 738–744
   PubMed Web of Science ®Google Scholar
• Lowsky R, Lipton J, Fyles G, Minden M, Meharchand J, Tejpar I, et al. Secondary malignancies after bone marrow transplantation in adults. J Clin Oncol 1994; 12: 2187–2192
   PubMed Web of Science ®Google Scholar
• Witherspoon R P, Fisher L D, Schoch G, Martin P, Sullivan K M, Sanders J, et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 1989; 321: 784–789
   PubMed Web of Science ®Google Scholar
• Rizzo J, Curtis R, Deeg H J. Long-term follow-up of allogeneic blood stem cell and bone marrow transplantation: a collaborative study of EBMT and IBMTR. Blood 2001; 98: 774A
   Google Scholar
• Curtis R E, Rowlings P A, Deeg H J, Shriner D A, Socie G, Travis L B, et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336: 897–904
   PubMed Web of Science ®Google Scholar
• de Vathaire F, Francois P, Hill C, Schweisguth O, Rodary C, Sarrazin D, et al. Role of radiotherapy and chemotherapy in the risk of second malignant neoplasms after cancer in childhood. Br J Cancer 1989; 59: 792–796
   PubMed Web of Science ®Google Scholar
• Garwicz S, Anderson H, Olsen J H, Dollner H, Hertz H, Jonmundsson G, et al. Second malignant neoplasms after cancer in childhood and adolescence: a population-based case-control study in the 5 Nordic countries. The Nordic Society for Pediatric Hematology and Oncology. The Association of the Nordic Cancer Registries. Int J Cancer 2000; 88: 672–678
   PubMed Web of Science ®Google Scholar
• Neglia J P, Friedman D L, Yasui Y, Mertens A C, Hammond S, Stovall M, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 2001; 93: 618–629
   PubMed Web of Science ®Google Scholar
• Leung W, Sandlund J T, Hudson M M, Zhou Y, Hancock M L, Zhu Y, et al. Second malignancy after treatment of childhood non-Hodgkin lymphoma. Cancer 2001; 92: 1959–1966
   PubMed Web of Science ®Google Scholar
• de Vathaire F, Hardiman C, Shamsaldin A, Campbell S, Grimaud E, Hawkins M, et al. Thyroid carcinomas after irradiation for a first cancer during childhood. Arch Intern Med 1999; 159: 2713–2719
   PubMed Web of Science ®Google Scholar
• Neglia J P, Meadows A T, Robison L L, Kim T H, Newton W A, Ruymann F B, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 325: 1330–1336
   PubMed Web of Science ®Google Scholar
• Pottern L M, Kaplan M M, Larsen P R, Silva J E, Koenig R J, Lubin J H, et al. Thyroid nodularity after childhood irradiation for lymphoid hyperplasia: a comparison of questionnaire and clinical findings. J Clin Epidemiol 1990; 43: 449–460
   PubMed Web of Science ®Google Scholar
• Ron E, Modan B, Preston D, Alfandary E, Stovall M, Boice J D, Jr. Thyroid neoplasia following low-dose radiation in childhood. Radiat Res 1989; 120: 516–531
   PubMed Web of Science ®Google Scholar
• Beaty O, III, Hudson M M, Greenwald C, Luo X, Fang L, Wilimas J A, et al. Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. J Clin Oncol 1995; 13: 603–609
   PubMed Web of Science ®Google Scholar
• Tarbell N J, Gelber R D, Weinstein H J, Mauch P. Sex differences in risk of second malignant tumours after Hodgkin's disease in childhood. Lancet 1993; 341: 1428–1432
   PubMed Web of Science ®Google Scholar
• Bhatia S, Robison L L, Oberlin O, Greenberg M, Bunin G, Fossati-Bellani F, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996; 334: 745–751
   PubMed Web of Science ®Google Scholar
• Hancock S L, Tucker M A, Hoppe R T. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 1993; 85: 25–31
   PubMed Web of Science ®Google Scholar
• Hawkins M M, Wilson L M, Burton H S, Potok M H, Winter D L, Marsden H B, et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 1996; 88: 270–278
   PubMed Web of Science ®Google Scholar
• Le Vu B, de Vathaire F, Shamsaldin A, Hawkins M M, Grimaud E, Hardiman C, et al. Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood. Int J Cancer 1998; 77: 370–377
   PubMed Web of Science ®Google Scholar
• Tucker M A, D'Angio G J, Boice J D, Jr, Strong L C, Li F P, Stovall M, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987; 317: 588–593
   PubMed Web of Science ®Google Scholar
• Gomez G A, Aggarwal K K, Han T. Post-therapeutic acute malignant myeloproliferative syndrome and acute nonlymphocytic leukemia in non – Hodgkin's lymphoma. Cancer 1982; 50: 2285–2288
   PubMed Web of Science ®Google Scholar
• Meadows A T, Baum E, Fossati-Bellani F, Green D, Jenkin R D, Marsden B, et al. Second malignant neoplasms in children: an update from the Late Effects Study Group. J Clin Oncol 1985; 3: 532–538
   PubMed Web of Science ®Google Scholar
• Pillon M, Di Tullio MT, Garaventa A, Cesaro S, Putti M C, Favre C, et al. Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92). Cancer 2004; 101: 385–394
   PubMed Web of Science ®Google Scholar
• Sandoval C, Pui C H, Bowman L C, Heaton D, Hurwitz C A, Raimondi S C, et al. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol 1993; 11: 1039–1045
   PubMed Web of Science ®Google Scholar
• Pyatt D W, Hays S M, Cushing C A. Do children have increased susceptibility for developing secondary acute myelogenous leukemia?. Chem Biol Interact 2005; 153/154: 223–229
   Web of Science ®Google Scholar
• Pui C H, Ribeiro R C, Hancock M L, Rivera G K, Evans W E, Raimondi S C, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991; 325: 1682–1687
   PubMed Web of Science ®Google Scholar
• Smith M A, Rubinstein L, Anderson J R, Arthur D, Catalano P J, Freidlin B, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 1999; 17: 569–577
   PubMed Web of Science ®Google Scholar
• Sugita K, Furukawa T, Tsuchida M, Okawa Y, Nakazawa S, Akatsuka J, et al. High frequency of etoposide (VP - 16)-related secondary leukemia in children with non-Hodgkin's lymphoma. Am J Pediatr Hematol Oncol 1993; 15: 99–104
   PubMedGoogle Scholar
• Smith M A, Rubinstein L, Cazenave L, Ungerleider R S, Maurer H M, Heyn R, et al. Report of the Cancer Therapy Evaluation Program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins. J Natl Cancer Inst 1993; 85: 554–558
   PubMed Web of Science ®Google Scholar
• German J. Bloom's syndrome. XX. The first 100 cancers. Cancer Genet Cytogenet 1997; 93: 100–106
   PubMed Web of Science ®Google Scholar
• Poppe B, Van Limbergen H, Van Roy N, Vandecruys E, De Paepe A, Benoit Y, et al. Chromosomal aberrations in Bloom syndrome patients with myeloid malignancies. Cancer Genet Cytogenet 2001; 128: 39–42
   PubMed Web of Science ®Google Scholar
• Makis A, Polychronopoulou S, Haidas S. Osteosarcoma as a second tumor after treatment for primary non-Hodgkin's lymphoma in a child with ataxia-telangiectasia: presentation of a case and review of possible pathogenetic mechanisms. J Pediatr Hematol Oncol 2004; 26: 444–446
   PubMed Web of Science ®Google Scholar
• Overberg-Schmidt U, Wegner R D, Baumgarten E, Gunther A, Ebell W, Stein H, et al. Low-grade non-Hodgkin's lymphoma after high-grade non-Hodgkin's lymphoma in a child with ataxia telangiectasia. Cancer 1994; 73: 1522–1525
   PubMed Web of Science ®Google Scholar